Search Page

1

Cite

Share

Commentary: confidentiality of interim trial data-the emerging crisis.

Nissen SE. Nissen SE. Clin Trials. 2015 Feb;12(1):15-7. doi: 10.1177/1740774514561661. Epub 2014 Dec 18. Clin Trials. 2015. PMID: 25525072 No abstract available.

Cite

Share

2

Cite

Share

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). Hicks KA, et al. Among authors: nissen se. Circulation. 2018 Feb 27;137(9):961-972. doi: 10.1161/CIRCULATIONAHA.117.033502. Circulation. 2018. PMID: 29483172 Review.

Cite

Share

3

Cite

Share

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K. Nissen SE, et al. N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21. N Engl J Med. 2007. PMID: 17517853 Free article.

Cite

Share

4

Cite

Share

Reforming the continuing medical education system.

Nissen SE. Nissen SE. JAMA. 2015 May 12;313(18):1813-4. doi: 10.1001/jama.2015.4138. JAMA. 2015. PMID: 25965221 No abstract available.

Cite

Share

5

Cite

Share

Setting the RECORD Straight.

Nissen SE. Nissen SE. JAMA. 2010 Mar 24;303(12):1194-5. doi: 10.1001/jama.2010.333. JAMA. 2010. PMID: 20332408 No abstract available.

Cite

Share

6

Cite

Share

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

Nissen SE, Wolski K, Topol EJ. Nissen SE, et al. JAMA. 2005 Nov 23;294(20):2581-6. doi: 10.1001/jama.294.20.joc50147. Epub 2005 Oct 20. JAMA. 2005. PMID: 16239637

Cite

Share

7

Cite

Share

An audience with... Steven Nissen.

Nissen S. Nissen S. Nat Rev Drug Discov. 2006 Feb;5(2):98. doi: 10.1038/nrd1971. Nat Rev Drug Discov. 2006. PMID: 16521326 No abstract available.

Cite

Share

8

Cite

Share

The complementary roles of imaging and 'omics' for future anti-atherosclerotic drug development.

Puri R, Nissen SE. Puri R, et al. Among authors: nissen se. Curr Pharm Des. 2013;19(33):5963-71. doi: 10.2174/13816128113199990365. Curr Pharm Des. 2013. PMID: 23438963 Review.

Cite

Share

9

Cite

Share

Atherosclerosis regression: is low-density lipoprotein or high-density lipoprotein the answer?

Nicholls SJ, Tuzcu EM, Nissen SE. Nicholls SJ, et al. Among authors: nissen se. Curr Atheroscler Rep. 2007 Oct;9(4):266-73. doi: 10.1007/s11883-007-0032-5. Curr Atheroscler Rep. 2007. PMID: 18173953 Review.

Cite

Share

10

Cite

Share

The Jupiter trial: key findings, controversies, and implications.

Nissen SE. Nissen SE. Curr Cardiol Rep. 2009 Mar;11(2):81-2. doi: 10.1007/s11886-009-0013-0. Curr Cardiol Rep. 2009. PMID: 19236822 No abstract available.

Cite

Share